Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Contrarian Investing -- Ignore unavailable to you. Want to Upgrade?

To: pcyhuang who wrote (308)	9/23/2006 1:39:35 PM
From: MACD X	Respond to of 4080

BSX CONTRARIAN VIEW HAS GOOD FRIENDS www2.barchart.com the link above is showing the highest percentage losers on the S&P500 of which BSX has the 499 out of 500 spot sewed up. But there is something interesting about the group on the page and that is there is some good companys in this group.. They are predominately large cap companys, I have been watching this group for a long period of time. It is about time where this group should take charge, The four year cycle low that everyone is looking for may in fact be a change of the guard, if this large caps take over the cap wieghted indexs will jump while the broad market may fall simular to the pre 2000 run up when large caps where the large gainers of the times. Just a contrarian view.

To: pcyhuang who wrote (308)	9/24/2006 11:43:18 PM
From: pcyhuang	Respond to of 4080

Growth of sales in implantable cardioverter-defibrillators (ICD) Full Story: nj.com Merrill Lynch analyst Glenn Reicin recently surveyed 75 physicians who implant defibrillators and concluded that sales will pick up again in the next 12 to 18 months. "Clinicians we surveyed were optimistic about the prospects for ICD market growth and do not be lieve that the recent slowdown will be permanent," Reicin wrote in an investor note last week. New uses for the underlying technology in defibrillators could include treatment of severe mi graines and other maladies, which could be a catalyst for sales once clinical trials proving their effectiveness are complete, analysts said. Until then, ICD makers are funding education and training efforts to convince more doctors to issue referrals for surgical implants. As part of that plan, Boston Scientific last month launched an ad campaign touting its cardiac-device business... pcyhuang

To: pcyhuang who wrote (308)	9/27/2006 10:17:41 AM
From: pcyhuang	Respond to of 4080

9/17/06 9:00AM Boston Scientific announces FDA approval of Harmony HiResolution Bionic Ear System (BSX) 14.80 : Co announces the approval of its new HarmonyHiResolution Bionic Ear System (Harmony System) by the FDA. Developed by the co's Neuromodulation Group, the Harmony System delivers 120 spectral bands helping to significantly increase hearing potential and quality of life for the severe-to-profoundly deaf. In addition to the FDA approval, the Harmony HiResolution Bionic Ear System recently received approval from Health Canada and the CE mark in Europe. The HiResolution Bionic Ear System with optional HiRes Fidelity 120 is approved in the U.S. for adults only at this time and for all patients in Canada and Europe. The product is expected to be available in early 2007. pcyhuang

To: pcyhuang who wrote (308)	10/9/2006 10:11:46 PM
From: pcyhuang	Respond to of 4080

BSX management's incentive business.bostonherald.com pcyhuang

To: pcyhuang who wrote (308)	10/19/2006 4:34:09 AM
From: pcyhuang	Read Replies (1) \| Respond to of 4080

BSX -- Swinging to Profit Boston Scientific Swings To $76 Million Profit Full Story: online.wsj.com BOSTON -- Boston Scientific Corp. on Wednesday said it swung to a $76 million third-quarter profit, a result that narrowly beat Wall Street estimates and follows a string of recent disappointments for the medical device maker after its $27 billion acquisition of Guidant Corp. Boston Scientific said net income for the July-September period equaled 5 cents per share, compared to a loss of $269 million, or 33 cents a share, in last year's third quarter, when Boston Scientific recorded a $598 million expense for a legal settlement. Sales rose from $1.51 billion in last year's third quarter to $2.03 billion, a 34% increase driven in part by $446 million in sales of defibrillator and pacemaker products that Boston Scientific acquired in the Guidant purchase, which closed in April. However, sales of Boston Scientific's top-selling product, the Taxus drug-coated stent, fell 5% from $601 million in last year's third quarter to $572 million in the most recent period. Boston Scientific and New Jersey-based Johnson & Johnson dominate the market for drug-coated stents, metal-mesh devices that prop open coronary arteries after artery-clearing surgery. Excluding $77 million in one-time expenses largely related to the Guidant acquisition, Boston Scientific's per-share profit equaled 10 cents per share, narrowly beating the consensus estimate of analysts surveyed by Thomson Financial, who expected a profit of 9 cents. That estimate includes stock-option expenses but does not include one-time charges. Boston Scientific's revenue of $2.026 billion also slightly exceeded the forecast of analysts, who expected revenue of $2.018 billion, on average. The performance followed a $4.26 billion loss that Boston Scientific reported in this year's second quarter, a result that was largely attributed to more than $4.5 billion in costs from the Guidant acquisition. Boston Scientific bought Guidant to acquire its lucrative defibrillator and pacemaker business, but the deal has helped drive the company's stock to a four-year low amid debt concerns. The downturn in the market for drug-coated stents is in part the result of recent research suggesting the devices may slightly increase the risk of blood clots compared with older bare-metal stents. Shares of the Natick, Mass., company, which reported results after the close of regular trading, were up nearly 3% in after-hours trading to $15.55. pcyhuang

To: pcyhuang who wrote (308)	11/6/2006 10:02:57 PM
From: pcyhuang	Read Replies (1) \| Respond to of 4080

BSX -- Surprising forecast for 2007 BSX forecasts 2007 revenue between $8.65 billion and $9.45 billion. This new forecast represents an increase of 11 to 21 percent from its estimated 2006 sales. The firm stated that it has targeted double-digit growth in both 2007 sales and earnings compared with estimated 2006 results. According to MarketWatch, analysts at Thomson First Call currently forecast earnings of 78 cents per share on revenue of $9.06 billion. pcyhuang